04.09.2008 Landmark research heralds new era in dog heart treatment and longer life for dogs 31.08.2008 First landmark ARB trial against placebo shows Micardis® (telmisartan) reduces the risk of cardiovascular death, heart attack and stroke in ACE-intolerant high-risk patients¹ For medical media, outside the US only 26.08.2008 Pramipexole clinical trial programme in Restless Legs Syndrome (RLS) reveals new significant results 25.08.2008 Boehringer Ingelheim to sign cooperation with HISOAR in China 25.08.2008 Role of pramipexole in key research areas of Parkinson’s disease management discussed at 12th EFNS Congress For medical media, outside the US only 21.08.2008 Cymbalta receives european approval for the treatment of Generalised Anxiety Disorder 19.08.2008 New data show Duloxetine maintained pain reduction for more than six months in patients with diabetic peripheral neuropathic pain 07.08.2008 Spiriva^®, Micardis^® and Flomax^® - Boehringer Ingelheim`s highly successful products show good growth. Excellent progress in Research and Development. Strong euro curbs growth. Expenditure in R&D+M reduces operating income. 05.08.2008 Closure of the tipranavir trials SPRING and TICINO 04.08.2008 New data shows HIV therapy tipranavir (Aptivus^®) is effective and well tolerated in children For medical media, outside the US only